Abstract: The method for preventing progression to Type II Diabetes includes determining whether a subject possesses a risk variant expression profile demonstrating dysregulation of the IL-33/ST2 axis, and providing an intervention to prevent progression to Type II Diabetes and/or to reverse prediabetes, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with Type II Diabetes or prediabetes, such as heart disease, stroke, or obesity. The pharmaceutical compound may be one or more pharmaceuticals capable of reducing circulating cholesterol, reducing blood glucose levels, reducing blood pressure, or a combination thereof.

Abstract: Methods of inhibiting MMP-9 are provided. The methods of inhibiting MMP-9 include methods of inhibiting IL-6/TNF-? crosstalk mediated expression and/or secretion of MMP-9. The inhibition of the IL-6/TNF-? crosstalk pathway may be accomplished using an IL-6 signaling inhibitor, such as AG490 or SC-144. The methods may also include the treatment of dieses through the inhibition of IL-6/TNF-? crosstalk mediated production of MMP-9. In an embodiment the methods may include preventing the progression of cancer or cardiovascular disease through the inhibition of the IL-6/TNF-? crosstalk pathway.

Abstract: The microRNA ANGPTL3 inhibitor includes methods of administering a miRNA capable of inhibiting ANGTPL3 and/or dyslipidemia to a subject in need thereof. The methods of administering the miRNA ANGPTL3 inhibitor may include administration of miRNA-181d to a subject in need thereof. The administration of miRNA-181d may inhibit ANGPTL3 activity, thereby reducing ANGPTL3's inhibition of lipoprotein lipase activity and increasing triglyceride degradation. The administration of miRNA-181d may be used to treat or prevent lipid metabolism disorders including dyslipidemia and dyslipidemia associated diseases, such as hyperlipidemia, atherosclerosis, heart disease, and the like.

Abstract: The microRNA dyslipidemia inhibitor includes methods of administering a miRNA capable of inhibiting dyslipidemia to a subject in need thereof. The methods of the miRNA dyslipidemia inhibitor may include administration of miRNA-103 to a subject in need thereof. The administration of miRNA-103 may inhibit ANGPTL8 activity, thereby reducing ANGPTL8's inhibition of lipoprotein lipase activity and increasing triglyceride degradation. The administration of miRNA-103 may be used to treat or prevent lipid metabolism disorders including dyslipidemia and dyslipidemia associated diseases, such as hyperlipidemia, atherosclerosis, heart disease, and the like.

Abstract: The method for preventing progression to metabolic syndrome includes determining whether a subject possesses at least one allele of the caveolin-1 rs1997623 C to A SNP, and providing an intervention to prevent progression to metabolic syndrome, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with MetS, such as heart disease, stroke, or diabetes. The method may include monitoring additional metabolic risk factors. The pharmaceutical compound may be a pharmaceutical capable of inhibiting the expression of caveolin-1.